Targeting Reticulin 4 (RTN4) Within Small Extracellular Vesicles Combats Metastasis and Reinforces Immunotherapy in Triple-Negative Breast Cancer
Quick Facts
- Publication title: Targeting Reticulin 4 (RTN4) Within Small Extracellular Vesicles Combats Metastasis and Reinforces Immunotherapy in Triple-Negative Breast Cancer
- Journal: J Extracell Vesicles
- Year: 2025
- DOI: 10.1002/jev2.70154
- PMID/PMCID: 40831287; PMC12365394
Research overview
In this study, we isolated sEV from non-metastatic and metastatic TNBC plasma samples. sEV protein RTN4 is a potential new prognostic marker for non-invasive detection of TNBC and a new target for TNBC treatment.
Key findings
Small extracellular vesicles (sEV) are a class of natural vesicles rich in heterogeneous cargos with the great advantage of non-invasive detection; these vesicles exhibit complex intercellular crosstalk and mediate important biological functions.
However, the potential value of plasma sEV in clinical prognosis prediction of triple-negative breast cancer (TNBC) and their biological functions have not been well elucidated.
In this study, we isolated sEV from non-metastatic and metastatic TNBC plasma samples.
We found that the expression of reticulin 4 (RTN4) in metastatic patients was significantly higher than that in non-metastatic patients.
Echo Biotech Role
Echo Biotech contributed EV isolation and purification; the study also used or cited Exosupur®.
Related platforms: Exoomics®, Research Reagents & Tools
Related services and capabilities: Biofluid EV Isolation & Purification, Research Reagent / Product Supply
Related products or reagents: Exosupur® EV Isolation/Purification Kit
References
Original publication: Targeting Reticulin 4 (RTN4) Within Small Extracellular Vesicles Combats Metastasis and Reinforces Immunotherapy in Triple-Negative Breast Cancer Journal of Extracellular Vesicles. 2025. DOI: 10.1002/jev2.70154. PMID/PMCID: 40831287; PMC12365394.